Objective.: To include the patient perspective in accordance with the Outcome Measures in Rheumatology (OMERACT) Filter 2.0 in the updated Psoriatic Arthritis (PsA) Core Domain Set for randomized controlled trials (RCT) and longitudinal observational studies (LOS).Methods.: At OMERACT 2016, research conducted to update the PsA Core Domain Set was presented and discussed in breakout groups. The updated PsA Core Domain Set was voted on and endorsed by OMERACT participants.Results.: We conducted a systematic literature review of domains measured in PsA RCT and LOS, and identified 24 domains. We conducted 24 focus groups with 130 patients from 7 countries representing 5 continents to identify patient domains. We achieved consensus through 2 rounds of separate surveys with 50 patients and 75 physicians, and a nominal group technique meeting with 12 patients and 12 physicians. We conducted a workshop and breakout groups at OMERACT 2016 in which findings were presented and discussed. The updated PsA Core Domain Set endorsed with 90% agreement by OMERACT 2016 participants included musculoskeletal disease activity, skin disease activity, fatigue, pain, patient’s global assessment, physical function, health-related quality of life, and systemic inflammation, which were recommended for all RCT and LOS. These were important, but not required in all RCT and LOS: economic cost, emotional well-being, participation, and structural damage. Independence, sleep, stiffness, and treatment burden were on the research agenda.Conclusion.: The updated PsA Core Domain Set was endorsed at OMERACT 2016. Next steps for the PsA working group include evaluation of PsA outcome measures and development of a PsA Core Outcome Measurement Set.

Background Treatment satisfaction among patients with moderate‐to‐severe psoriasis has not been studied and compared across treatments using a validated instrument. Objectives To assess patient‐reported satisfaction with systemic and phototherapy treatments for moderate‐to‐severe psoriasis in clinical practice and to correlate satisfaction with disease severity and quality‐of‐life measures. Methods This was a cross‐sectional study of 1182 patients with moderate‐to‐severe psoriasis in the Dermatology Clinical Effectiveness Research Network in the U.S.A. Patients receiving either topical therapies only; monotherapy with oral systemic therapies, biologics or narrowband ultraviolet B phototherapy; or combination therapy with biologics and methotrexate completed the Treatment Satisfaction Questionnaire for Medication version II. Results Median unadjusted overall satisfaction scores were highest for patients receiving biologic monotherapies, biologic–methotrexate combinations, or phototherapy (83·3); scores were lowest for those receiving topical therapies only or acitretin (66·7). In fully adjusted models, compared with patients receiving methotrexate monotherapy, those receiving adalimumab, etanercept, ustekinumab, phototherapy or adalimumab with methotrexate had significantly higher median overall satisfaction scores by 7·2–8·3 points, while those receiving topical therapies only had significantly lower overall satisfaction by 8·9 points. Adjusted convenience scores were lowest for patients receiving topical therapies only or infliximab. Modest but significant correlations were found between the overall satisfaction subscale and both the Psoriasis Area and Severity Index (ρ = −0·36, P < 0·001) and the Dermatology Life Quality Index (ρ = −0·47, P < 0·001). Conclusions Discernible differences were found in treatment satisfaction among therapies, particularly regarding treatment effectiveness and convenience. Further application of treatment satisfaction measures may inform treatment decisions and guideline development.

Psoriasis is a common, chronic inflammatory disease of the skin and joints mediated by types 1 and 17 helper T cells.^1,2 It can develop at any age, but onset most commonly occurs in young adulthood. The disease is believed to be incurable and long-term spontaneous remissions are rare. Psoriasis is associated with impairment in physical and emotional health even in patients with mild disease, and patients with psoriasis requiring systemic therapy or phototherapy (ie, those with moderate to severe disease) have an increased risk of major cardiovascular events and mortality independent of traditional risk factors.^3-9